Cargando…

Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study

Despite decades of concerted epidemiological research, relatively little is known about the etiology of prostate cancer. As genome‐wide association studies have identified numerous genetic variants, so metabolomic profiling of blood and other tissues represents an agnostic, “broad‐spectrum” approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondul, Alison M., Moore, Steven C., Weinstein, Stephanie J., Karoly, Edward D., Sampson, Joshua N., Albanes, Demetrius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537663/
https://www.ncbi.nlm.nih.gov/pubmed/25904191
http://dx.doi.org/10.1002/ijc.29576
_version_ 1782385925777522688
author Mondul, Alison M.
Moore, Steven C.
Weinstein, Stephanie J.
Karoly, Edward D.
Sampson, Joshua N.
Albanes, Demetrius
author_facet Mondul, Alison M.
Moore, Steven C.
Weinstein, Stephanie J.
Karoly, Edward D.
Sampson, Joshua N.
Albanes, Demetrius
author_sort Mondul, Alison M.
collection PubMed
description Despite decades of concerted epidemiological research, relatively little is known about the etiology of prostate cancer. As genome‐wide association studies have identified numerous genetic variants, so metabolomic profiling of blood and other tissues represents an agnostic, “broad‐spectrum” approach for examining potential metabolic biomarkers of prostate cancer risk. To this end, we conducted a prospective analysis of prostate cancer within the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention Study cohort based on 200 cases (100 aggressive) and 200 controls (age‐ and blood collection date‐matched) with fasting serum collected up to 20 years prior to case diagnoses. Ultrahigh performance liquid chromatography/mass spectroscopy and gas chromatography/mass spectroscopy identified 626 compounds detected in >95% of the men and the odds ratio per 1‐standard deviation increase in log‐metabolite levels and risk were estimated using conditional logistic regression. We observed strong inverse associations between energy and lipid metabolites and aggressive cancer (p = 0.018 and p = 0.041, respectively, for chemical class over‐representation). Inositol‐1‐phosphate showed the strongest association (OR = 0.56, 95% CI = 0.39–0.81, p = 0.002) and glycerophospholipids and fatty acids were heavily represented; e.g., oleoyl‐linoleoyl‐glycerophosphoinositol (OR = 0.64, p = 0.004), 1‐stearoylglycerophosphoglycerol (OR=0.65, p = 0.025), stearate (OR=0.65, p = 0.010) and docosadienoate (OR = 0.66, p = 0.014). Both alpha‐ketoglutarate and citrate were associated with aggressive disease risk (OR = 0.69, 95% CI = 0.51–0.94, p = 0.02; OR = 0.69, 95% CI = 0.50–0.95, p = 0.02), as were elevated thyroxine and trimethylamine oxide (OR = 1.65, 95% CI = 1.08–2.54, p = 0.021; and OR = 1.36, 95% CI = 1.02–1.81, p = 0.039). Serum PSA adjustment did not alter the findings. Our data reveal several metabolomic leads that may have pathophysiological relevance to prostate carcinogenesis and should be examined through additional research.
format Online
Article
Text
id pubmed-4537663
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-45376632016-09-16 Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study Mondul, Alison M. Moore, Steven C. Weinstein, Stephanie J. Karoly, Edward D. Sampson, Joshua N. Albanes, Demetrius Int J Cancer Epidemiology Despite decades of concerted epidemiological research, relatively little is known about the etiology of prostate cancer. As genome‐wide association studies have identified numerous genetic variants, so metabolomic profiling of blood and other tissues represents an agnostic, “broad‐spectrum” approach for examining potential metabolic biomarkers of prostate cancer risk. To this end, we conducted a prospective analysis of prostate cancer within the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention Study cohort based on 200 cases (100 aggressive) and 200 controls (age‐ and blood collection date‐matched) with fasting serum collected up to 20 years prior to case diagnoses. Ultrahigh performance liquid chromatography/mass spectroscopy and gas chromatography/mass spectroscopy identified 626 compounds detected in >95% of the men and the odds ratio per 1‐standard deviation increase in log‐metabolite levels and risk were estimated using conditional logistic regression. We observed strong inverse associations between energy and lipid metabolites and aggressive cancer (p = 0.018 and p = 0.041, respectively, for chemical class over‐representation). Inositol‐1‐phosphate showed the strongest association (OR = 0.56, 95% CI = 0.39–0.81, p = 0.002) and glycerophospholipids and fatty acids were heavily represented; e.g., oleoyl‐linoleoyl‐glycerophosphoinositol (OR = 0.64, p = 0.004), 1‐stearoylglycerophosphoglycerol (OR=0.65, p = 0.025), stearate (OR=0.65, p = 0.010) and docosadienoate (OR = 0.66, p = 0.014). Both alpha‐ketoglutarate and citrate were associated with aggressive disease risk (OR = 0.69, 95% CI = 0.51–0.94, p = 0.02; OR = 0.69, 95% CI = 0.50–0.95, p = 0.02), as were elevated thyroxine and trimethylamine oxide (OR = 1.65, 95% CI = 1.08–2.54, p = 0.021; and OR = 1.36, 95% CI = 1.02–1.81, p = 0.039). Serum PSA adjustment did not alter the findings. Our data reveal several metabolomic leads that may have pathophysiological relevance to prostate carcinogenesis and should be examined through additional research. John Wiley and Sons Inc. 2015-05-09 2015-11-01 /pmc/articles/PMC4537663/ /pubmed/25904191 http://dx.doi.org/10.1002/ijc.29576 Text en © 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Epidemiology
Mondul, Alison M.
Moore, Steven C.
Weinstein, Stephanie J.
Karoly, Edward D.
Sampson, Joshua N.
Albanes, Demetrius
Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study
title Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study
title_full Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study
title_fullStr Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study
title_full_unstemmed Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study
title_short Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study
title_sort metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha‐tocopherol, beta‐carotene cancer prevention (atbc) study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537663/
https://www.ncbi.nlm.nih.gov/pubmed/25904191
http://dx.doi.org/10.1002/ijc.29576
work_keys_str_mv AT mondulalisonm metabolomicanalysisofprostatecancerriskinaprospectivecohortthealphatocopherolbetacarotenecancerpreventionatbcstudy
AT moorestevenc metabolomicanalysisofprostatecancerriskinaprospectivecohortthealphatocopherolbetacarotenecancerpreventionatbcstudy
AT weinsteinstephaniej metabolomicanalysisofprostatecancerriskinaprospectivecohortthealphatocopherolbetacarotenecancerpreventionatbcstudy
AT karolyedwardd metabolomicanalysisofprostatecancerriskinaprospectivecohortthealphatocopherolbetacarotenecancerpreventionatbcstudy
AT sampsonjoshuan metabolomicanalysisofprostatecancerriskinaprospectivecohortthealphatocopherolbetacarotenecancerpreventionatbcstudy
AT albanesdemetrius metabolomicanalysisofprostatecancerriskinaprospectivecohortthealphatocopherolbetacarotenecancerpreventionatbcstudy